Enochian BioSciences Forges Ahead With Focused Approach, Promising Future
Author: Benzinga Newsdesk | October 24, 2022 08:08am
(NASDAQ:ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world's deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center.
Posted In: ENOB